(Q34521105)

2 August 2017

Keep off the grass? Cannabis, cognition and addiction (English)

1 reference

2 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

David A. Lewis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

H Valerie Curran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Claire Mokrysz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Celia J A Morgan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Loren H Parsons

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

7 April 2016

1 reference

Nature Reviews Neuroscience

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

293-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27052382%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrn.2016.28

2 June 2020

exact match

0 references

cites work

Cannabinoids for Medical Use

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adverse health effects of marijuana use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabidiol enhances consolidation of explicit fear extinction in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Metabolic effects of chronic cannabis smoking

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9-Tetrahydrocannabinol-Tolerant Rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The Endocannabinoid Signaling System in the CNS: A Primer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Early phytocannabinoid chemistry to endocannabinoids and beyond.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoid signaling and synaptic plasticity in the brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effects of δ9-tetrahydrocannabinol on human working memory function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Hippocampal harms, protection and recovery following regular cannabis use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Segmental hair analysis for 11-nor-Δ⁹-tetrahydrocannabinol-9-carboxylic acid and the patterns of cannabis use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dysfunctional prefrontal cortical network activity and interactions following cannabinoid receptor activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabis and adolescent brain development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Differential effects of delta9-THC on learning in adolescent and adult rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effects of cannabis on the adolescent brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Specific attentional dysfunction in adults following early start of cannabis use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Age of onset of marijuana use and executive function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Persistent cannabis users show neuropsychological decline from childhood to midlife

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The role of puberty in the developing adolescent brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Neuropsychological sex differences associated with age of initiated use among young adult cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Sex differences in the adolescent brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Neuropsychological performance in long-term cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Neurocognitive consequences of marihuana--a comparison with pre-drug performance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Neurocircuitry of addiction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Is there a common molecular pathway for addiction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Drug Addiction: Updating Actions to Habits to Compulsions Ten Years On.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Opiate versus psychostimulant addiction: the differences do matter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Molecular mechanisms of cannabinoid addiction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Review of the validity and significance of cannabis withdrawal syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Corticotropin releasing factor: a key role in the neurobiology of addiction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Self-administration of cannabinoids by experimental animals and human marijuana smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Examining the profile of high-potency cannabis and its association with severity of cannabis dependence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The clinical relevance of attentional bias in substance use disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Two brain sites for cannabinoid reward.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endogenous cannabinoids as an aversive or counter-rewarding system in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoid receptors and reward in the rat: a conditioned place preference study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoid signalling in reward and addiction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The dopamine theory of addiction: 40 years of highs and lows

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Mesolimbic dopaminergic decline after cannabinoid withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Imaging dopamine transmission parameters in cannabis dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Onset of opportunity to use cannabis and progression from opportunity to dependence: Are influences consistent across transitions?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Candidate genes for cannabis use disorders: findings, challenges and directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

"Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The endocannabinoid system in guarding against fear, anxiety and stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The emerging role of the endocannabinoid system in the sleep-wake cycle modulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Pharmacological treatment of cannabis dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The endocannabinoid system as a target for the treatment of cannabis dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Mental health differences between frequent cannabis users with and without dependence and the general population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Testing hypotheses about the relationship between cannabis use and psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

CB1 receptor-deficient mice as a model for depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Endocannabinoid-mediated synaptic plasticity and addiction-related behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effect of anxiety on treatment presentation and outcome: results from the Marijuana Treatment Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Characteristics of clinically anxious versus non-anxious regular, heavy marijuana users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Investigating the interaction between schizotypy, divergent thinking and cannabis use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Daily marijuana use is not associated with brain morphometric measures in adolescents or adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Vaping cannabis (marijuana) has the potential to reduce tobacco smoking in cannabis users.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effects of Schedule I drug laws on neuroscience research and treatment innovation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The 'grass ceiling': limitations in the literature hinder our understanding of cannabis use and its consequences.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabis and educational achievement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Young adult sequelae of adolescent cannabis use: an integrative analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The effects of adolescent cannabis use on educational attainment: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

A systematic review of the relationship between high school dropout and substance use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Marijuana use and high school dropout: the influence of unobservables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Associations of alcohol, nicotine, cannabis, and drug use/dependence with educational attainment: evidence from cotwin-control analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabis Use and Earlier Onset of Psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Elevated endogenous cannabinoids in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Targeting the endocannabinoid system: to enhance or reduce?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Escalation of drug use in early-onset cannabis users vs co-twin controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Augmented acquisition of cocaine self-administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid agonist during adolescence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Evaluating alternative cannabis regimes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Prior exposure to THC increases the addictive effects of nicotine in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Modulation of Delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Periadolescent exposure to cannabinoids alters the striatal and hippocampal dopaminergic system in the adult rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRN.2016.28

The European Monitoring Centre for Drugs and Drug Addiction publishes the European Drug Report 2013: trends and developments

31 March 2020

1 reference

12 December 2020

Pharmacotherapies for cannabis dependence

1 reference

12 December 2020

Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report

1 reference

12 December 2020

Cannabis use and memory brain function in adolescent boys: a cross-sectional multicenter functional magnetic resonance imaging study

1 reference

12 December 2020